Design Therapeutics, Inc. (NASDAQ:DSGN – Get Free Report) has earned an average rating of “Hold” from the seven brokerages that are currently covering the stock, Marketbeat reports. Seven analysts have rated the stock with a hold rating. The average 1 year price target among brokerages that have issued a report on the stock in the […]
Design Therapeutics, Inc. (NASDAQ:DSGN – Get Free Report) has received an average recommendation of “Hold” from the seven research firms that are currently covering the company, MarketBeat.com reports. Seven equities research analysts have rated the stock with a hold rating. The average 1-year target price among brokers that have issued ratings on the stock in […]
Shares of Design Therapeutics, Inc. (NASDAQ:DSGN – Get Free Report) have received a consensus rating of “Hold” from the seven ratings firms that are currently covering the company, MarketBeat.com reports. Seven research analysts have rated the stock with a hold rating. The average 12 month price target among brokerages that have issued a report on […]
Design Therapeutics (NASDAQ:DSGN – Free Report) had its price target decreased by Royal Bank of Canada from $7.00 to $4.00 in a report published on Tuesday morning, Benzinga reports. Royal Bank of Canada currently has a sector perform rating on the stock. A number of other research firms have also issued reports on DSGN. SVB […]
Design Therapeutics, Inc. (NASDAQ:DSGN – Get Free Report) was the target of a large increase in short interest in October. As of October 31st, there was short interest totalling 3,120,000 shares, an increase of 6.1% from the October 15th total of 2,940,000 shares. Based on an average trading volume of 938,000 shares, the short-interest ratio […]